SCHEMBL1611070

SCHEMBL1611070

Cc1ccc2oc3ccc(C)cc3c(=O)c2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPG P10696 1/20 0.59
MAPT P10636 10/20 0.57
NPC1 O15118 6/20 0.57
RAB9A P51151 6/20 0.57
SMN1; SMN2 Q16637 6/20 0.57
GFER P55789 1/20 0.57
KDM4E B2RXH2 9/20 0.57
ALDH1A1 P00352 8/20 0.57
HPGD P15428 5/20 0.57
CASP3 P42574 1/20 0.57
SENP8 Q96LD8 1/20 0.57
SENP7 Q9BQF6 1/20 0.57
SENP6 Q9GZR1 1/20 0.57
HSD17B10 Q99714 3/20 0.54
PKM P14618 1/20 0.54
HTT P42858 2/20 0.53
CSNK2A2 P19784 5/20 0.53
CSNK2B P67870 5/20 0.53
CSNK2A1 P68400 5/20 0.53
TP53 P04637 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9980172 0.92 ALPG (0.53) ALPGMAPTNPC1RAB9ASMN1; SMN2
Xanthone SCHEMBL11252075 0.90 MAOA (0.67) ALPGMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL352535 0.90 MAOA (0.67) ALPGMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL19217398 0.89 CSNK2A2 (0.62) ALPGMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL16477278 0.89 MAPT (0.60) ALPGMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL21467921 0.87 CSNK2A2 (0.50) ALPGMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL24398597 0.86 NPC1 (0.55) ALPGMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL16477276 0.86 MAPT (0.83) MAPTNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL16477277 0.86 CSNK2A2 (0.62) ALPGMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL26936175 0.86 MAPT (0.51) ALPGMAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9318712-B2 Xanthone compound and organic light-emitting device including the same CANON KABUSHIKI KAISHA (JP) 2016-04-19 US disclosed
US-9269911-B2 Organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2016-02-23 US disclosed
US-9163002-B2 Methodology for the synthesis of xanthones UNIVERSITY OF SOUTH CAROLINA (US) 2015-10-20 US disclosed
US-9090819-B2 Organic electroluminescent element, display device, illuminating device and condensed polycyclic heterocyclic compound Konica Minolta, Inc. (JP) 2015-07-28 US disclosed
US-9090819-B2 Organic electroluminescent element, display device, illuminating device and condensed polycyclic heterocyclic compound Konica Minolta, Inc. (JP) 2015-07-28 US disclosed
US-20140107354-A1 New Methodology for the Synthesis of Xanthones UNIVERSITY OF SOUTH CAROLINA 2014-04-17 US disclosed
US-20130214268-A1 XANTHONE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CANON KABUSHIKI KAISHA (JP) 2013-08-22 US disclosed
US-20130037791-A1 ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2013-02-14 US disclosed
US-20120085997-A1 ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, ILLUMINATING DEVICE AND CONDENSED POLYCYCLIC HETEROCYCLIC COMPOUND KONICA MINOLTA HOLDINGS, INC. (JP) 2012-04-12 US disclosed
US-20120085997-A1 ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, ILLUMINATING DEVICE AND CONDENSED POLYCYCLIC HETEROCYCLIC COMPOUND KONICA MINOLTA HOLDINGS, INC. (JP) 2012-04-12 US disclosed
US-7175958-B2 Electrophotographic photoconductor, process for forming an image, image forming apparatus and process cartridge for the same RICOH COMPANY, LTD. (JP) 2007-02-13 US disclosed
US-7175958-B2 Electrophotographic photoconductor, process for forming an image, image forming apparatus and process cartridge for the same RICOH COMPANY, LTD. (JP) 2007-02-13 US disclosed
US-4250182-A Pharmaceutical composition containing acridone compounds and method of using same BURROUGHS WELLCOME CO. (US) 1981-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140107354-A1 New Methodology for the Synthesis of Xanthones XDH, TYR, NISCH ALPG 263/4885MAPT 2203/4885NPC1 3426/4885
US-20120085997-A1 ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, ILLUMINATING DEVICE AND CONDENSED POLYCYCLIC HETEROCYCLIC COMPOUND CCNE2, C1S, SCO2 ALPG 1440/4885MAPT 4576/4885NPC1 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.